IDEXX Laboratories, Inc.: financial statements

IDXXNASDAQHealthcare · In Vitro & In Vivo Diagnostic Substances

Price

$676.21

November 20, 2026Market cap $53.8B

What Ploutos Investor adds for IDEXX Laboratories

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+8.4% a year over 2 years

Line202320242025Average a year
Revenue $3.7B$3.9B$4.3B+8.4%
Cost of revenue $1.5B$1.5B$1.6B+5.7%
Gross profit $2.2B$2.4B$2.7B+10.2%
Operating income $1.1B$1.1B$1.4B+11.3%
Net income $845M$888M$1.1B+12.0%
Earnings per share $10.06$10.67$13.08+14.0%
Earnings per share, basic $10.17$10.77$13.17+13.8%
Margins
Gross margin 59.8%61.0%61.8%
Operating margin 30.0%29.0%31.6%
Net margin 23.1%22.8%24.6%

Financial statements

IDXX's revenue, profits and cash flows from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: Companion Animal Group $3.4B, Water $168M, Livestock And Poultry Diagnostics $122M
  • 2024: Companion Animal Group $3.6B, Water $185M, Livestock And Poultry Diagnostics $122M
  • 2025: Companion Animal Group $4.0B, Water $201M, Livestock And Poultry Diagnostics $132M
Segment202320242025Share 2025
Companion Animal Group$3.4B$3.6B$4.0B92%
Water$168M$185M$201M4.7%
Livestock And Poultry Diagnostics$122M$122M$132M3.1%

By segment

IDXX's revenue by segment from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 16 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$150M Due within 2 years$128M Leases265% Pensions funded

When the debt falls due

Dec 31, 2025

Due within 2 years

$150M

Total falling due

$450M

Total in the ladder $450M, from the annual report dated December 31, 2025. Principal of loans and bonds, without leases and interest. The filing

  • 2026: $75M
  • 2027: $75M
  • 2028: $0
  • 2029: $100M
  • 2030: $200M
  • 2031 on: –

The ladder at each year end

Year1 yr2 yrs3 yrs4 yrs5 yrsLater
2025$75M$75M$0$100M$200M–
2024$168M$75M$75M$0$100M$200M
2023$75M$173M$75M$75M$0$300M

The ladder at each year end

When IDXX's debt fell due, as each annual report set it out, from 2011 to 2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Leases

Dec 31, 2025

Operating leases

$128M

Finance leases

–

Average discount rate
4.3%

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

IDXX's leases from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Pension plans

Dec 31, 2024

Defined-benefit pensions

265%funded

Surplus $9.4M.

The obligation is the present value of the pensions employees have already earned, at December 31, 2024. A deficit is the company's to fill with contributions. The filing

ObligationPlan assets

Goodwill by segment

Dec 31, 2025

Total goodwill

$414M

  • Companion Animal Group$374M
  • Water$18M
  • Livestock And Poultry Diagnostics$15M

The segments the company states do not add up to the total at December 31, 2025: a piece is missing. The filing

$414MTotal goodwill

Goodwill by year

Goodwill by year

IDXX's goodwill from 2010 to 2022, 13 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

20.0%

-1.0 pts

The company paid 20.0% in tax on its profit, 1.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

State and local taxes

+2.5 pts

Non-deductible expenses

+0.5 pts

Share-based compensation

-1.8 pts

Tax credits

-1.1 pts

Cross-border effects

-0.6 pts

Uncertain tax positions

-0.6 pts

Smaller lines (2)

+0.1 pts

Effective rate

20.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

Effective tax rate by year

The tax rate IDXX paid on its profit, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Where the change in earnings per share came from

Diluted earnings per share went from $10.67 in the fiscal year to Dec 31, 2024 to $13.08 in the year to Dec 31, 2025, a change of +$2.41.

Measured by size, 17.8% of the movement came from outside sales and operating margin: interest and other items, the tax rate, what went to others and the share count.

+$1.20
+$1.06
-$0.17
$0.00
+$0.32

Earnings per share is split as sales times operating margin, plus interest and other items, after tax, times the part that goes to the common shareholders, divided by the diluted share count. Each source's part is its average effect over every order in which the six can change, so the parts add up exactly to the change. From the annual reports; net income over the diluted count matches the earnings per share the company filed within 2%.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were +9.9% on the same quarter a year earlier, and receivables +8.6%. Inventory was -0.2%, against +6.7% for the cost of sales.

a year earlier 47 days
46 days
a year earlier 85 days
79 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Taxes: deferred and paid

The deferred part was 49.6% of the tax charge in the year to Dec 31, 2025. The rows show the last 3 years.

Cash taxes paid were 125.4% of the current tax charge in the year to Dec 31, 2025.

Deferred share, year to Dec 31, 2025$131M of $265M
49.6%
Deferred share, year to Dec 31, 2024-$24M of $222M
-10.9%
Deferred share, year to Dec 31, 2023-$48M of $216M
-22.4%
$167M paid, $134M current
125.4%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

What the company measures itself

The operating figures management reports in its annual report beyond the financial statements: subscribers, deliveries, stores, backlog. Each figure as the company writes it, with the sentence it comes from, and only when the company reports it in two consecutive years that agree with each other.

  • Catalyst installed baseCatalyst 78 74 69
    Latest year78.0K2025
    Change+5.3%
  • Premium Hematology installed basePremium Hematology 56 52 48
    Latest year56.0K2025
    Change+8.1%
  • SediVue Dx installed base24 21 18
    Latest year24.0K2025
    Change+12.7%
  • Growth in installed base of premium instrumentsVolume gains were supported by increases in testing, including the benefits from 12% growth in our installed base of premium instruments
    Latest year12.0%2025
    Change–
  • Recurring diagnostic revenue as share of consolidated revenuerecurring diagnostic revenue, which is both highly durable and profitable, accounted for approximately 79% of our consolidated revenue.
    Latest year79.0%2025
    Change–
  • Organic revenue growthTotal Company $ 4,303,702 $ 3,897,504 $ 406,198 10.4 % 0.8 % — 9.6 %
    Latest year9.6%2025
    Change–
  • U.S. same-store growth in average diagnostics revenue per practiceIn the U.S., average diagnostics revenue per practice grew approximately 6% on a same-store basis during 2025
    Latest year6.0%2025
    Change–

Catalyst installed base

Click a metric in the table below to see it here.

  • Latest year78.0K2025
    Change+5.3%
  • Latest year56.0K2025
    Change+8.1%
  • Latest year24.0K2025
    Change+12.7%
  • Latest year12.0%2025
    Change–
  • Latest year79.0%2025
    Change–
  • Latest year9.6%2025
    Change–
  • Latest year6.0%2025
    Change–
  • Latest year10.5%2023
    Change–
  • Latest year9.5%2023
    Change–
  • Latest year7.6%2023
    Change–

What the company measures itself

The metrics IDXX measures itself, from 2015 to 2022, 8 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

The full analysis

What do IDEXX Laboratories's filings show?

These are IDEXX Laboratories's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about IDXX's financials

Didn't find what you were looking for?

Ask us
How much revenue did IDXX have in 2025?

IDEXX Laboratories had revenue of $4.3B and net income of $1.1B in fiscal 2025, a net margin of 24.6%.

How much debt does IDXX have?

On December 31, 2025 IDEXX Laboratories had total assets of $3.4B, debt of $450M and shareholders' equity of $1.6B.

How much free cash flow does IDXX have?

In fiscal 2025 IDEXX Laboratories had cash from operations of $1.2B and spent $125M on capital expenditure, leaving $1.1B of free cash flow.

Where are the figures from?

From IDEXX Laboratories, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.